The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.

Allergenic substances, allergens, are captured by topically applicable preparations comprising peptides that consist of 2-10 amino acids, at least one amino acid having one or more reactive side chains. The preparation comprises antioxidants and/or the pH of the preparation is less than 7. This barrier effect of the preparation allows for a novel anti-allergic form of therapy.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

A nutritional health supplement is provided for the brain. In one exemplary embodiment, a nutritional health supplement comprises a first neuroprotective agent having antioxidant, anti-inflammatory, anti-apoptic, anti-autophagic, and anti-cerebral edema properties, and having calcium-induced apoptotic signaling-inhibiting properties; a second neuroprotective agent having glutamate-mediated excitotoxicity-mitigating and calcium influx-mitigating properties and having antioxidant and blood-brain barrier protecting properties; a third neuroprotective agent that is a precursor for glutathione synthesis and has calcium influx-mitigating and anti-oxidative stress mediating properties and that augments the first neuroprotective agent's calcium-induced apoptotic signaling-inhibiting properties and anti-cerebral edema properties and the second neuroprotective agent's antioxidant properties; a NAD+ precursor that augments the first neuroprotective agent's anti-apoptotic properties, the second neuroprotective agent's glutamate-mediated excitotoxicity-mitigating and blood-brain barrier protecting properties, and the third neuroprotective agent's calcium influx-mitigating and anti-oxidative stress mediating properties. The second neuroprotective agent augments the third neuroprotective agent's calcium influx-reducing property.

The present invention patent application relates essentially to an additive, the function of which is to enhance immunity, prevent various diseases and increase detoxification of the organism. The additive is composed of: 60 mcg of vitamin A; 4.5 mg of vitamin C; 1 mg of vitamin E; 3.4 mcg of selenium; 0.5 mg of copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyme Q10; 5 mg of pycnogenol; 0.13 mg of vitamin B2; 1.6 mg of vitamin B3; 0.13 mg of vitamin B6; 24 mcg of folic acid; 0.24 mcg of vitamin B12; 2 mg of glutathione; 100 mg of leucine; 20 mg of isoleucine; 20 mg of valine; 50 mg of glycine; 50 mg of taurine; 300 mg of glutamine; 60 mg of acetylcysteine; 50 mg of cysteine; 100 mg of methionine; 0.5 mg of vitamin B5; 2 mg of lycopene; and 4 mg of resveratrol.

The present invention patent application relates essentially to an additive, the function of which is to enhance immunity, prevent various diseases and increase detoxification of the organism. The additive is composed of: 60 mcg of vitamin A; 4.5 mg of vitamin C; 1 mg of vitamin E; 3.4 mcg of selenium; 0.5 mg of copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyme Q10; 5 mg of pycnogenol; 0.13 mg of vitamin B2; 1.6 mg of vitamin B3; 0.13 mg of vitamin B6; 24 mcg of folic acid; 0.24 mcg of vitamin B12; 2 mg of glutathione; 100 mg of leucine; 20 mg of isoleucine; 20 mg of valine; 50 mg of glycine; 50 mg of taurine; 300 mg of glutamine; 60 mg of acetylcysteine; 50 mg of cysteine; 100 mg of methionine; 0.5 mg of vitamin B5; 2 mg of lycopene; and 4 mg of resveratrol.

The present disclosure relates to methods for preventing, treating and/or reducing the severity of conditions or diseases associated with coronavirus infections. The methods comprise of administering an effective amount of a pharmaceutically acceptable compound which is an antioxidant or a substance capable of increasing the level of glutathione in the body. Preferably, the compound is a glutathione precursor selected from cysteine or a derivative thereof, cystine or a derivative thereof, methylsulfonylmethane (MSM) and dimethyl sulfoxide (DMSO), in particular, the glutathione precursor is N-acetylcysteine (NAC). In some embodiments, the compound is selected from lipoic acid, glycine, glutamate, or a derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.

The present disclosure relates to methods for preventing, treating and/or reducing the severity of conditions or diseases associated with coronavirus infections. The methods comprise of administering an effective amount of a pharmaceutically acceptable compound which is an antioxidant or a substance capable of increasing the level of glutathione in the body. Preferably, the compound is a glutathione precursor selected from cysteine or a derivative thereof, cystine or a derivative thereof, methylsulfonylmethane (MSM) and dimethyl sulfoxide (DMSO), in particular, the glutathione precursor is N-acetylcysteine (NAC). In some embodiments, the compound is selected from lipoic acid, glycine, glutamate, or a derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.

The embodiments herein relate to the combination of herbal and probiotic (optionally with prebiotic) treatment for chronic liver diseases to be novel and more effective. Embodiments herein relate to a composition comprising a probiotic and a medicinal herb (and optionally a prebiotic), wherein the composition is effective in treating a liver disease such as inflammation of liver in a novel approach to disease management. The combination of a prebiotic, a probiotic and a medicinal herb constitutes a symbiotic formulation. Clinical and animal data exists to show efficacy of these combinations. The ingredients, as well as the categories, in the combination are novel. Using a combination of twelve herbs and three probiotics, a highly efficacious and novel supplement is disclosed herein. Embodiments of the compositions herein could further include homeopathic drugs and an active pharmaceutical ingredient such as an allopathic drug.

Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (VI) ##STR00001##
wherein R.sub.1 and R.sub.2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.